China Myasthenia Gravis Market

ID: MRFR/HC/47610-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026
China Myasthenia Gravis Market Research Report: Size, Share, Trend Analysis By Disease Type (Acetylcholine Receptor Antibody Positive Myasthenia Gravis, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, Seronegative Myasthenia Gravis), By Treatment Type (Anticholinesterase Agents, Immunosuppressants, Intravenous Immunoglobulin, Plasmapheresis, Thymectomy), By Route of Administration (Oral, Intravenous, Subcutaneous) and By End Users (Hospitals, Specialty Clinics, Homecare Settings) - Growth Outlook & Industry Forecast 2025 To 2035
China Myasthenia Gravis Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.31%
2024 Market Size$ 104.64 Million
2025 Market Size$ 112.29 Million
2035 Market Size$ 227.3 Million
Key Players
Roche
Bristol-Myers Squibb
Novartis
Sanofi
Pfizer
Merck & Co.
Trends
  • Emergence of Novel Therapies
  • Increased Patient Awareness
  • Regulatory Support for Research
Opportunities
  • Increased Focus on Rare Diseases
  • Rising Incidence of Myasthenia Gravis
  • Advancements in Diagnostic Technologies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Disease Type (USD Million)
      1. 4.1.1 Acetylcholine Receptor Antibody Positive Myasthenia Gravis
      2. 4.1.2 Muscle-Specific Kinase Antibody Positive Myasthenia Gravis
      3. 4.1.3 Seronegative Myasthenia Gravis
    2. 4.2 Life Sciences, BY Treatment Type (USD Million)
      1. 4.2.1 Anticholinesterase Agents
      2. 4.2.2 Immunosuppressants
      3. 4.2.3 Intravenous Immunoglobulin
      4. 4.2.4 Plasmapheresis
      5. 4.2.5 Thymectomy
    3. 4.3 Life Sciences, BY Route of Administration (USD Million)
      1. 4.3.1 Oral
      2. 4.3.2 Intravenous
      3. 4.3.3 Subcutaneous
    4. 4.4 Life Sciences, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Specialty Clinics
      3. 4.4.3 Homecare Settings
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Amgen (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eisai (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY DISEASE TYPE
    3. 6.3 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 CHINA MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
    9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    12. 6.12 LIFE SCIENCES, BY DISEASE TYPE, 2024 (% SHARE)
    13. 6.13 LIFE SCIENCES, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE)
    15. 6.15 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    17. 6.17 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    18. 6.18 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
    19. 6.19 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Myasthenia Gravis Market Segmentation

China Myasthenia Gravis Market By Disease Type (USD Million, 2025-2035)

  • Acetylcholine Receptor Antibody Positive Myasthenia Gravis
  • Muscle-Specific Kinase Antibody Positive Myasthenia Gravis
  • Seronegative Myasthenia Gravis

China Myasthenia Gravis Market By Treatment Type (USD Million, 2025-2035)

  • Anticholinesterase Agents
  • Immunosuppressants
  • Intravenous Immunoglobulin
  • Plasmapheresis
  • Thymectomy

China Myasthenia Gravis Market By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Intravenous
  • Subcutaneous

China Myasthenia Gravis Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Specialty Clinics
  • Homecare Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.